Efficacy and Safety of Anagrelide as a First‐line Drug in Cytoreductive Treatment‐naïve Essential Thrombocythemia Patients in a Real‐world Setting

European Journal of Haematology - United Kingdom
doi 10.1111/ejh.13265
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

First‐line Treatment of Essential Hypertension: A Real‐world Analysis Across Four Antihypertensive Treatment Classes

Journal of Clinical Hypertension
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2019English

Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia

New England Journal of Medicine
Medicine
2005English

Takotsubo Cardiomyopathy in a Patient With Essential Thrombocythemia Treated With Anagrelide: Case Report

Cor et Vasa
Cardiovascular MedicineCardiology
2018English

The Use of Anagrelide in Myeloproliferative Neoplasms, With Focus on Essential Thrombocythemia

Current Hematologic Malignancy Reports
Cancer ResearchOncologyHematology
2016English

Efficacy and Safety of XEN®—Implantation vs. Trabeculectomy: Data of a “Real-World” Setting

PLoS ONE
Multidisciplinary
2020English

Prinzmetal Angina in a Young Patient With Essential Thrombocythemia, After Anagrelide Initiation - Case Report and Literature Review

ARS Medica Tomitana
BiochemistryMedicineGeneticsMolecular Biology
2018English

HIV-1 Drug Resistance Genotyping From Antiretroviral Therapy (ART) Naïve and First-Line Treatment Failures in Djiboutian Patients

Diagnostic Pathology
Forensic MedicineMedicinePathologyHistology
2012English

Treatment of Hepatitis C Genotype 1 Infection in Germany: Effectiveness and Safety of Antiviral Treatment in a Real-World Setting

United European Gastroenterology Journal
OncologyGastroenterology
2017English

P2.01-36 Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy